

Mutations in Histone Acetylase Modifier *BRPF1* Cause an Autosomal-Dominant Form of Intellectual Disability with Associated Ptosis

Francesca Mattioli,^{1,2,3,4,5} Elise Schaefer,⁶ Alex Magee,⁷ Paul Mark,⁸ Grazia M. Mancini,⁹ Klaus Dieterich,¹⁰ Gretchen Von Allmen,¹¹ Marielle Alders,¹² Charles Coutton,¹³ Marjon van Slegtenhorst,⁹ Gaëlle Vieville,¹³ Mark Engelen,¹² Jan Maarten Cobben,¹² Jane Juusola,¹⁴ Aurora Pujol,^{15,16,17} Jean-Louis Mandel,^{1,2,3,4,5,18,19,*} and Amélie Piton^{1,2,3,4,18,*}

Intellectual disability (ID) is a common neurodevelopmental disorder exhibiting extreme genetic heterogeneity, and more than 500 genes have been implicated in Mendelian forms of ID. We performed exome sequencing in a large family affected by an autosomal-dominant form of mild syndromic ID with ptosis, growth retardation, and hypotonia, and we identified an inherited 2 bp deletion causing a frameshift in *BRPF1* (c.1052_1053del) in five affected family members. *BRPF1* encodes a protein modifier of two histone acetyltransferases associated with ID: *KAT6A* (also known as *MOZ* or *MYST3*) and *KAT6B* (*MORF* or *MYST4*). The mRNA transcript was not significantly reduced in affected fibroblasts and most likely produces a truncated protein (p.Val351Glyfs*8). The protein variant shows an aberrant cellular location, loss of certain protein interactions, and decreased histone *H3K23* acetylation. We identified *BRPF1* deletions or point mutations in six additional individuals with a similar phenotype. Deletions of the 3p25 region, containing *BRPF1* and *SETD5*, cause a defined ID syndrome where most of the clinical features are attributed to *SETD5* deficiency. We compared the clinical symptoms of individuals carrying mutations or small deletions of *BRPF1* alone or *SETD5* alone with those of individuals with deletions encompassing both *BRPF1* and *SETD5*. We conclude that both genes contribute to the phenotypic severity of 3p25 deletion syndrome but that some specific features, such as ptosis and blepharophimosis, are mostly driven by *BRPF1* haploinsufficiency.

Intellectual disability (ID) characterizes a group of neurodevelopmental disorders that constitute a major public health, social, and educational problem because of the cumulated frequency and the heavy burden for affected individuals and families. ID is defined by significant limitations in both intellectual functioning and adaptive behavior associated with an intellectual quotient (IQ) below 70, and it affects about 2% of children or young adults. Moderate to severe forms of ID can be caused by chromosomal anomalies, including pathogenic deletions or duplications or single-gene defects with recessive, X-linked, or autosomal-dominant inheritance. More than 500 genes have been implicated in Mendelian forms of ID. Mutations can cause non-syndromic or syndromic ID with other associated clinical features. Additionally, a number of recurrent microdeletions also cause ID.

Terminal 3p and interstitial deletions of the 3p25–p26 region cause 3p deletion syndrome (MIM: 613792), characterized by mild to severe ID, growth retardation, micro-

cephaly, and dysmorphic features, notably ptosis.¹ The terminal or interstitial deletions range from large deletions of several megabases to smaller deletions of fewer than 500 kb and do not always overlap, rendering it difficult to identify the genes associated with the phenotype. An increasing number of individuals harboring deletions of this region has advanced the understanding of the critical genes for this 3p25 region. Several individuals with a small 3p25.3 distal deletion present with a non-3p phenotype with ID, epilepsy, poor speech, ataxia, and stereotypic hand movements, and the two genes encoding GABA transporters, *SLC6A1* (MIM: 137165) and *SLC6A11* (MIM: 607952), were suspected to be involved.² For the more proximal deletions in 3p25, the most promising gene appears to be *SETD5* (MIM: 615743), encoding a putative histone methyltransferase. Indeed, variations in *SETD5* in individuals with ID and clinical features consistent with the 3p deletion syndrome have recently been reported.^{3–5} However, some clinical features recurrent in 3p25 deletion syndrome, such as ptosis and

¹Institut de Genetique et de Biologie Moleculaire et Cellulaire, 67400 Illkirch-Graffenstaden, France; ²INSERM U964, 67400 Illkirch-Graffenstaden, France; ³CNRS UMR 7104, 67400 Illkirch-Graffenstaden, France; ⁴Université de Strasbourg, 67400 Illkirch, France; ⁵Chaire de Génétique Humaine, Collège de France, 67400 Illkirch, France; ⁶Service de Génétique Médicale, Hôpitaux Universitaires de Strasbourg, Institut de Génétique Médicale d'Alsace, 67000 Strasbourg, France; ⁷Genetic Medicine, Belfast City Hospital, Belfast BT9 7AB, Ireland; ⁸Spectrum Health Medical Group, Grand Rapids, MI 49544, USA; ⁹Department of Clinical Genetics, Erasmus MC, Rotterdam 3015, the Netherlands; ¹⁰Service de Génétique Clinique, Centre Hospitalier Universitaire de Grenoble site Nord, Hôpital Couple-Enfant, 38700 Grenoble, France; ¹¹Department of Pediatrics, McGovern Medical School, University of Texas in Houston, Houston, TX 77030, USA; ¹²Department of Clinical Genetic, Academic Medical Center, Amsterdam 1100, the Netherlands; ¹³INSERM 1209, CNRS UMR 5309, Laboratoire de Génétique Chromosomique, Centre Hospitalier Universitaire Grenoble Alpes, Institut Albert Bonniot, Université Grenoble Alpes, 38700 Grenoble, France; ¹⁴GeneDx, Gaithersburg 20877, USA; ¹⁵Neurometabolic Diseases Laboratory, Institute of Neuropathology, Institut d'Investigació Biomèdica de Bellvitge, 08908 Barcelona, Spain; ¹⁶Center for Biomedical Research on Rare Diseases U759, L'Hospitalet de Llobregat, 08908 Barcelona, Spain; ¹⁷Catalan Institution for Research and Advanced Studies, 08010 Barcelona, Spain; ¹⁸Laboratoire de diagnostic génétique, Institut de Génétique Médicale d'Alsace, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France; ¹⁹University of Strasbourg Institute for Advanced studies, 67000 Strasbourg, France

*Correspondence: jmandel@igbmc.fr (J.-L.M.), piton@igbmc.fr (A.P.)

<http://dx.doi.org/10.1016/j.ajhg.2016.11.010>

© 2017 American Society of Human Genetics.

blepharophimosis, are not consistently observed in individuals with *SETD5* mutations.

Here, we investigated the genetic origin of an autosomal-dominant syndromic form of mild ID associated with other features such as growth retardation, ptosis, and relative microcephaly, present in six affected relatives over three generations (Figure 1A). Ethical approval was obtained from the local ethics committees. The proband, III-2, was born at term with intrauterine growth restriction: weight 2,900 g (fifth percentile), height 46 cm (third percentile), and head circumference 32.5 cm (third percentile). Bilateral clubfeet were diagnosed during the pregnancy, and a karyotype was performed but was negative. At birth, edema of the back of the feet was noticed. He was hospitalized at the age of 1 month for the association of hypotonia and eating disorders without weight gain. The clinical examination found dysmorphic features with left ptosis, bilateral epicanthus, anteverted nostrils, a round face, a long philtrum, small and round ears, and unilateral cryptorchidism (Figure 3). Brachymetacarpia and clinodactyly of the toes were also noticed. Echocardiography, renal ultrasound, and cerebral echography found no anomaly. The cerebral computed tomography scan and hearing were normal. Gastroesophageal reflux was diagnosed. His development was significant for growth restriction and development of psychomotor delay. At 4 months old, the proband weighed 4,950 g (−1.5 SDs) and had a length of 54 cm (−3 SDs) and a head circumference of 39.5 cm (−1.5 SDs). At 4 years old, he weighed 14 kg (−1 SD) and had a length of 94 cm (−2 SDs) and a head circumference of 48.5 cm (−2 SDs). The boy sat at 16 months and walked at 30 months of age. He also presented with delayed language, and toilet training was acquired at 4 years of age. He had surgery for his ptosis and for cryptorchidism. His older brother (III-1) presented with no ID, growth disorder, or facial dysmorphism. However, his mother (II-2) presented with mild ID (permitting professional integration), short stature (150 cm), bilateral ptosis, facial dysmorphism similar to that of her son, and brachymetacarpia. Familial history revealed that her mother (deceased) and two of her sisters presented with the same phenotype. The phenotype is more severe for sister II-5, who had surgery twice for her ptosis with limited results and has had limited employment (Figure 3). She also presented with hypothyroidism. The other sister (II-3) also had surgery twice for her ptosis with limited results (Figure 3). She was 153 cm tall. Her daughter (III-4) presented with bilateral ptosis and mild ID with learning difficulties and concentration problems. Secondly, the mother (II-2) had a new pregnancy: fetal echography showed a suspected anomaly of foot positioning, indicating possible clubfeet. At birth, the baby (III-3) had normal growth parameters: he weighed 3,560 g and had a length of 48 cm and a head circumference of 35 cm. He presented with pes varus, edema of the back of the feet, and the same facial dysmorphism as that of his brother. Progressively, the child presented with growth retardation,

relative microcephaly, and developmental delay. At 19 months old, he could not walk. He weighed 8.2 kg (−3 SDs) and had a length of 75 cm (−2 SDs) and a head circumference of 45 cm (−2.5 SDs). His DNA was not available for testing. The child III-4, a cousin of the index individual, was born at term with short stature (47 cm), a normal weight (3,050 g), and a normal head circumference (33 cm). Bilateral ptosis was rapidly diagnosed and surgically repaired. Her motor development was within acceptable limits, given that she could sit at 8 months and walked at 18 months. Later, she presented with delayed language, difficulties at school, and behavioral disorders. Echocardiography, electroencephalogram, cerebral MRI, and a hearing test were normal. Unlike that of her cousins, her growth was normal: at 5.5 years, she weighed 22 kg and had a length of 114 cm and a head circumference of 50 cm. On clinical examination, the child presented with the same familial dysmorphism. Since then, the parents have had another child, who is in good health without developmental delay or facial dysmorphism.

The most severely affected individual (III-2) underwent multiple genetic tests before we decided to perform whole-exome sequencing (WES). In addition to karyotype, array comparative genomic hybridization, and fragile-X testing, many tests have been conducted, including evaluation of 22q11.2 (MIM: 611867) and 22q13.3 (MIM: 606232) deletion syndromes (by fluorescence in situ hybridization), as well as Prader-Willi (MIM: 176270) (15q11.2–q13 DNA methylation), DM1 myotonic dystrophy (MIM: 160900) (*DMPK* [MIM: 605377] expansion), Aarskog (MIM: 305400) (*FGD1* [MIM: 300546] sequencing), Noonan (MIM: 163950) (*PTPN11* [MIM: 176876], *SOS1* [MIM: 182530], *RAF1* [MIM: 164760], *SHOC2* [MIM: 602775] sequencing), and Saethre Chotzen (MIM: 101400) (*TWIST1* [MIM: 601622] and *FGFR3* [MIM: 134934] sequencing) syndromes.

Given that no pathogenic genetic event could be identified by these genetic investigations, we performed WES for individual III-2, his maternal cousin (III-4), and his maternal aunt (II-5). Libraries and captures from genomic blood DNA were done with the SureSelect XT Human All Exon V5 Kit (Agilent Technologies), and sequencing was performed on a 100 bp paired-end run on the HiSeq 2500 sequencer (Illumina). Reads were aligned and variants were called and annotated as previously described.^{6,7} To identify a variant shared by the three affected individuals, we used the family barcode given by the VaRank ranking program.⁶ Then, we filtered out the frequent mutations by using public databases and a large cohort of ID-affected individuals as previously described.⁷ Applying these criteria, we identified four candidate variants: one loss-of-function (LoF) and three missense variants in the heterozygous state in all three affected members. The three missense variants, c.650G>A (p.Arg217His) (GenBank: NM_080668.3) in *CDCA5* (MIM: 609374), c.143C>T (p.Ser48Leu) (GenBank: NM_005199) in *CHRNA1* (MIM: 100730), and c.1279C>T (p.Pro427Ser)




Figure 1. Identification of a Co-segregating 2 bp Deletion, c.1052_1053del, in *BRPF1* in a Family with Three Generations Affected by a Form of Mild ID Associated with Ptosis

(A) Pedigree of family A, which has three affected generations.

(B) The mutation partially escapes NMD. Quantitative real-time PCR was performed on RNA extracted (three extractions per individual) from fibroblasts of individual II-5 and three unrelated control individuals. The expression of *BRPF1* in relation to the average of two reference genes, *GAPDH* and *18S*, was calculated by the $2^{-\Delta\Delta C_t}$ method. A t test was performed and showed no significant difference in the *BRPF1* mRNA level (error bars indicate the SD of three independent experiments). Sequences of blood DNA and fibroblast cDNA (treated or not with the NMD-blocker emetine) from individual II.5 are shown on the right.

(C) Expression of *BRPF1* in HeLa cells. HeLa cells transfected with HA-tagged wild-type or p.Val351Glyfs*8 *BRPF1* cDNA. Cells were harvested 36 hr after transfection. *BRPF1* expression was analyzed by SDS-PAGE, and immunoblotting was performed with anti-HA antibody.

(D) HeLa cells were transfected with HA-tagged wild-type or p.Val351Glyfs*8 *BRPF1* cDNA. *BRPF1* localization was visualized by immunofluorescence with an anti-HA antibody. Nuclei were colored in blue by Hoechst staining.

(E) HA-tagged wild-type or mutant *BRPF1* was transfected along with expression plasmids for FLAG-tagged KAT6A, HA-tagged ING5, and HA-tagged MEAF6 into HEK293 cells. HAT complexes were immunoprecipitated from protein extracts with anti-FLAG antibody to pull down KAT6A, and products of the complex were revealed by western blot using anti-HA antibody.

(GenBank: NM_198517) in *TBC1D10C* (MIM: 610831), were unlikely to be considered pathogenic for the syndromic ID phenotype (Table S1). The unique LoF variant

identified was a 2 nt deletion, c.1052_1053del (GenBank: NM_001003694.1) in *BRPF1* (MIM: 602410), which encodes bromodomain and PHD finger-containing protein 1.




Figure 2. Mutations in *BRPF1* and Deletions in the 3p25 Region

(A) Overview of 3p25 deletions reported in the literature and in DECIPHER (from the UCSC Genome Browser). Black lines indicate a deletion encompassing both *SETD5* and *BRPF1*; orange lines represent the deletion containing *SETD5* but not *BRPF1*; and red lines indicate the two deletions including *BRPF1* but not *SETD5* reported in DECIPHER.

(B) Pedigree of the two additional families affected by 3p25 deletions encompassing *BRPF1* but not *SETD5*.

(C) Pedigree of four additional families with the *BRPF1* pathogenic variants shown in (D).

(legend continued on next page)

This deletion occurred in a well-conserved region, according to PhastCons and USCS Multiz alignment of 100 vertebrates and orthologs (from Ensembl), and was predicted to cause a frameshift leading to a premature stop codon eight amino acids downstream. Sanger sequencing in available family members confirmed that affected individuals carried deletion c.1052_1053del (Figure 1A), which has been added to ClinVar.

To evaluate whether *BRPF1* is tolerant of protein-truncating variants, we looked in the Exome Aggregation Consortium (ExAC) Browser, which contains 60,706 exomes from individuals unaffected by severe pediatric diseases. Here, we found five variants potentially leading to LoF in *BRPF1*: one nonsense and four splice variants. The nonsense variant is reported in one individual but present in only 21% of reads, suggesting a mosaic status (Table S2). The four splice variants are present in the heterozygous state. One of them is present in several (six) individuals but affects a known processed non-coding transcript (Ensembl: ENST00000469066.1). The three remaining variants are present in one individual each and affect canonical splice sites of exon 8 (324 nucleotides; might create an in-frame deletion of 108 amino acids), exon 9 (285 nucleotides; might create an in-frame deletion of 95 amino acids), or exon 11 (137 nucleotides; might create a frameshift). On the basis of gene length, 36 LoF variants in the *BRPF1* coding region could be expected for this gene; however, only five have been reported.⁸ These data suggest that *BRPF1* is an extremely LoF-intolerant gene (probability of LoF intolerance = 1).

To investigate whether the mutant *BRPF1* transcript undergoes nonsense-mediated decay (NMD), we obtained dermal fibroblasts from skin biopsy of individual II-5 and three unrelated control individuals. They were expanded as previously described.⁹ Fibroblast RNA was extracted according to the TRI Reagent protocol (Molecular Research Center), treated with DNaseI (Roche Diagnostic), and reverse transcribed into cDNA with random hexamers and SuperScript II Reverse Transcriptase according to the manufacturer's recommendation. PCR was performed with specific primers (*BRPF1* 5'-tgccagaacagcaatgtcatctc-3' [forward] and 5'-cgcacaggctccatcttcatgtaa-3' [reverse]). qPCR were performed in triplicate, and the *BRPF1* mRNA level was quantified by the $2^{-\Delta\Delta C_t}$ method with an average of two reference genes, *GAPDH* and *18S*. A parametric Student's t test was performed to compare the relative *BRPF1* expression and revealed a slight but not significant decrease in *BRPF1* mRNA levels in individual II-5, suggesting that the mutated transcript partially escapes NMD. cDNA sequencing (GATC) from II-5 revealed the presence of both the wild-type and the mutant transcripts (Figure 1B),

but peak heights were lower for the latter. A similar peak height could be restored when fibroblasts from individual II.5 were treated with emetine (100 μ g/mL) to block NMD, confirming that the c.1052_1053del *BRPF1* transcript undergoes partial NMD.

The deletion leads to a frameshift with the appearance of a premature stop codon: p.Val351Glyfs*8. The truncated protein is predicted to contain 358 amino acids instead of 1,220 and lacks several essential functional domains, including the second PHD finger domain, the bromodomain, and the PWWP domains, which are involved in histone recognition and binding (Figure 2D). We were not able to detect wild-type BRPF1 by western blot in fibroblasts from control individuals with the anti-BRPF1 antibody (Peregrin N-16, sc-103110, Santa Cruz Biotechnology; PCRB-BRPF1-2A12, DSHB, University of Iowa). To evaluate the protein, we generated N-terminal HA-tagged wild-type and mutant BRPF1. HeLa cells were transfected (Lipofectamine 2000, Invitrogen), and total proteins were extracted after 36 hr. Western blot using anti-HA antibody revealed an ~50 kDa truncated BRPF1 that accumulated at a lower level than the wild-type, suggesting reduced stability (Figure 1C). Using fluorescence microscopy, we observed that wild-type BRPF1 localized to the cytoplasm with the formation of cytoplasmic puncta, as previously reported (Figure 1D).¹² By contrast, the mutant BRPF1 signal was weaker, and the truncated protein appeared to be more uniformly distributed in both the cytoplasm and nucleus.

BRPF1 is a chromatin regulator that promotes histone acetylation by bringing different histone acetyltransferases (HATs) of the MYST protein family (HBO1, KAT6A [also known as MOZ], and KAT6B [MORF]) into a complex with other regulator proteins, such as ING5 and MEAF6.^{12,13} The truncated protein, p.Val351Glyfs*8, still contains the KAT6B and KAT6A interaction domains between amino acids 59 and 222.¹² A similarly truncated form of BRPF1 (Δ N-term1, truncated after amino acid 354) was still able to bind KAT6A.¹³ However, the ING5-MEAF6 interaction is mediated by amino acids 540–640,¹² suggesting that p.Val351Glyfs*8 BRPF1 would not be able to bring these two proteins into the HAT complex. To test this, we transfected HA-tagged wild-type and p.Val351Glyfs*8 BRPF1, along with expression plasmids for FLAG-tagged KAT6A, HA-tagged ING5, and HA-tagged MEAF6, into HEK293 cells. The HAT complexes were immunoprecipitated from protein extracts with anti-FLAG antibody to pull down KAT6A, and products were analyzed by western blot using anti-HA antibody (Figure 1E). We observed that both wild-type and p.Val351Glyfs*8 BRPF1 were able to bind KAT6A. Whereas

(D) Top: schematic representation of BRPF1 and localization of the five different LoF and missense mutations. Bottom: the four de novo LoF variants described by the DDD project in individuals with neurodevelopmental conditions¹⁰ (in dark blue) and the LoF variant identified in one boy with schizophrenia and mild ID.¹¹ Domains are colored as follows: yellow, PHD finger (PHD) domains; green, bromodomain (Bromo), involved in the recognition of acetylated lysine residues; blue, PWWP nucleosome-binding domain. Regions involved in binding with MOZ, MORF, ING5, and EAF6 are underlined.¹²

the wild-type was able to bind ING5 and MEAF6, the p.Val351Glyfs*8 variant failed to do so.

To investigate the effect of the *BRPF1* mutation on the global acetylation level of histone H3, we extracted histones from the fibroblasts of individual II-5 and three unrelated healthy control individuals. We used 2 μ g of histone proteins to detect global histone H3 acetylation with the EpiQuik Global Histone H3 Acetylation Assay Kits (Epigentek) (Figure S1A). No significant difference in H3 acetylation levels was detected. To dissect more specifically the acetylation occurring at the different lysines known to be acetylated by the KAT6A-KAT6B HAT complex,^{14,15} we performed western blot analysis on histone extractions with specific anti-H3K9 (ab4441, Abcam), anti-H3K14 (in house), and anti-H3K23 (9674, Cell Signaling) antibodies, and we normalized the intensities obtained to the intensity of global histone H3 (catalog no. 06755, lot 31949, Upstate). No change in acetylation levels was observed for H3K9 or K14 (Figure S1B); however, compared with control individuals, individual II-5 showed a slight but non-significant decrease in the acetylation level of H3K23. Histone H3 acetylation levels were also analyzed in histone extracts obtained from HeLa cells co-transfected with constructs encoding KAT6A, ING5, and MEAF6 with or without wild-type or p.Val351Glyfs*8 *BRPF1*. No difference was observed in the ability to stimulate K9 and K14 acetylation between wild-type and mutant *BRPF1*. However, unlike wild-type *BRPF1*, the p.Val351Glyfs*8 variant failed to stimulate K23 acetylation of histone H3 (Figure S1C).

BRPF1-KAT6A-KAT6B complexes are involved in the development of the forebrain and other organs in mice, and complete knockout causes embryonic lethality with vascular defects and abnormal neural tube closure.¹⁶ Inactivation in mice and other animal models, including medaka fish, has demonstrated that *BRPF1* acts through the regulation of *Hox* genes to effect skeletal development.^{13,17} To determine whether *BRPF1* also alters *HOX* expression in humans, we investigated the expression of human homologs of some *Hox* genes described as regulated by the murine *BRPF1*-KAT6A-KAT6B complex in individual II-5 fibroblasts. Results obtained for *HOXA7* (MIM: 142950) and *HOXC10* (MIM: 605560) were not interpretable as a result of variability in expression among control individuals (data not shown). However, low variability was observed in control individuals for the *HOXD8* (MIM: 142985) mRNA level, and we observed that the level of *HOXD8* mRNA was significantly higher in individual II-5 than in control individuals (Figure S2).

In order to confirm the association between *BRPF1* and ID, we performed data exchange to retrieve additional individuals carrying *BRPF1* mutations. We first queried DECIPHER to identify copy-number variants affecting *BRPF1* and identified two individuals with 3p25 deletions including *BRPF1* but not *SETD5* (a gene previously associated with ID) (Figure 2A). Clinical details of these two individuals are compared to the clinical symptoms of the first

family (Tables 1 and 2; Table S3). The first individual has a de novo 172 kb deletion encompassing *BRPF1* and four other genes (family B individual 6; Figure 2B). The second has a 181 kb deletion including *BRPF1* and eight other genes (family C individual 7; Figure 2B; Figure 3); this was inherited from her mildly affected mother (individual 8). Both individuals have mild ID, ptosis or blepharophthalmosis, and a roundish face, clinical features that overlap those of members of the large family. Next, we used the GeneMatcher exchange database to search for ID-affected individuals with *BRPF1* mutations identified by WES analysis (where no other obvious candidate gene was present). We found three nonsense or frameshift variations—c.2982C>G (p. Tyr994*), c.567delT (p.Asp190Metfs*24), and c.104dupA (p.Tyr35*)—and one de novo missense variant, c.1165T>C (p.Cys389Arg) (Figure 2C). Two of the nonsense mutations occurred de novo, and one was from unknown inheritance (in an adopted boy with a family history in his biological family; no DNA was available for testing). The missense variant affects a well-conserved amino acid located in the second PHD domain and is predicted to be pathogenic (by SIFT and PolyPhen-2). These four individuals presented with mild to moderate ID, hand and feet anomalies, and similar facial appearances with the presence of ptosis (Tables 1 and 2; Table S3; Figure 3). In total, all individuals with *BRPF1* mutations or deletions have mild or moderate ID. Of the three individuals with moderate ID, two (individuals 10 and 11) carry the earliest truncating mutations, whose protein products would lack at least part of the interaction domain with KAT6A and KAT6B. This truncated protein product might increase the severity of the phenotype, but we cannot exclude other genetic or environmental modifiers in the variable expressivity of this disorder.

De novo truncating variants in *BRPF1* have also been recently reported in large studies: the Deciphering Developmental Disorders (DDD) study has reported four de novo LoF variations in *BRPF1*—c.1883_1886dup (p.Gln629Hisfs*34), c.2117dup (p.Val707Argfs*8), c.2497C>T (p.Arg833*), and c.2915dup (p.Met973Asnfs*24), identified in 4,293 UK individuals with neurodevelopmental disorders.¹⁰ A de novo LoF variant was also reported in *BRPF1* in one male individual from a schizophrenia cohort.¹¹

3p25 deletion syndrome is characterized by ID, growth retardation, microcephaly, hypotonia, and specific facial dysmorphism. The critical region contains *BRPF1* and *SETD5*, among other genes. Previous work has established that disruption of *SETD5* is involved in the cognitive phenotype of this 3p25 syndrome.^{3–5} The identification of LoF mutations and deletions of *BRPF1* in individuals with ID led us to investigate the contribution of *BRPF1* in the 3p25 syndrome. We performed a genotype-phenotype comparison by using those individuals with mutations affecting either *BRPF1* (group 1) or *SETD5* (group 2) only as well as those with a 3p25 deletion including both *SETD5* and *BRPF1* (group 3) (Table 3; Table S3). For

Table 1. Clinical Features of Individuals Carrying *BRPF1* Mutations in Families A and B

| | Family A | | | | | Family B |
|---|------------------------------------|----------------------------------|----------------------------------|----------------------------------|-----------------------------------|---|
| | Individual 1 (III.2) | Individual 2 (II.2) | Individual 3 (II.3) | Individual 4 (III.4) | Individual 5 (II.5) | Individual 6 |
| Mutation (GenBank: NM_001003694.1) ^a | c.1052_1053del (p.Val351Glyfs*8) | c.1052_1053del (p.Val351Glyfs*8) | c.1052_1053del (p.Val351Glyfs*8) | c.1052_1053del (p.Val351Glyfs*8) | c.1052_1053del (p.Val351Glyfs*8) | deletion of chr3: 9,724,693–9,896,683 |
| Mutation type | intragenic | intragenic | intragenic | intragenic | intragenic | NA, de novo |
| Sex | male | female | female | female | female | male |
| Age of examination | 5 years, 9 months | 32 years | 34 years | 6 years, 10 months | 30 years | 6 years, 6 months |
| Uneventful pregnancy | diagnosis of club feet | NA | NA | yes | NA | no (36.5 WoG) |
| Birth weight | <5 th % | NA | NA | normal | NA | 3 rd % |
| Birth length | <3 rd % | NA | NA | <5 th % | NA | NA |
| Birth OFC | <3 rd % | NA | NA | <5 th % | NA | NA |
| Neonatal hypotonia | yes | NA | NA | no | NA | no |
| Hypotonia | yes | NA | NA | yes | NA | no |
| Small stature | yes (104.5 cm; <3 rd %) | yes (150 cm; <3 rd %) | yes (153 cm; <3 rd %) | no (122 cm) | yes (152 cm; <3 rd %) | no (113 cm) |
| Low weight | yes (16 kg; <3 rd %) | no (62 kg) | no (67 kg) | no (25 kg; >90 th %) | NA | no (21 kg) |
| ID | mild | mild | mild | mild | mild | mild |
| Microcephaly | mild (50 cm; <10 th %) | no (54.5 cm) | yes (53 cm; <3 rd %) | no (50 cm) | mild (54 cm; <10 th %) | mild (50.3 cm; <10 th %) |
| Brain anomalies (MRI) | ACC (rostrum) | NA | NA | no | NA | NA |
| Seizures | no | no | no | no | no | no |
| Delay in walking | yes | NA | NA | yes | NA | no |
| Speech delay | yes | NA | NA | yes | NA | mild |
| Behavioral anomalies | no | no | no | hyperactivity | no | hyperactivity, shy, quiet |
| Vision or eye problems | strabismus, amblyopia | refraction problems | refraction problems | refraction problems | strabismus, amblyopia | NA |
| Ptosis and/or blepharophimosis | yes | yes | yes | yes | yes | yes (bilateral) |
| Hand anomalies | BM, BD | BM, BD | BM, BD | BM, BD | BM, BD | bilateral CD of fifth finger |
| Feet anomalies | clinodactyly, club feet | no | NA | no | no | syndactyly of the second and third toes |

Abbreviations are as follows: %, percentile; ACC, agenesis of corpus callosum; BD, brachydactyly; BM, brachymetacarpia; CD, camptodactyly; MRI, magnetic resonance imaging; NA, information not available; OFC, occipital frontal circumference; and WoG, weeks of gestation.

^aThe mutation was absent from all of the available unaffected individuals in family A.

Table 2. Clinical Features of Individuals Carrying *BRPF1* Mutations or Deletions in Families C–G

| | Family C | | Family D | Family E | Family F | Family G |
|------------------------------------|---------------------------------------|---------------------|-----------------------------------|-------------------------------------|------------------------------|----------------------------|
| | Individual 7 | Individual 8 | Individual 9 | Individual 10 | Individual 11 | Individual 12 |
| Mutation (GenBank: NM_001003694.1) | deletion of chr3: 9,632,462–9,813,339 | | c.2982 C>G (p. Tyr994*) | c.567delT (p.Asp190Metfs*24) | c.104dupA (p.Tyr35*) | c.1165T>C (p.Cys389Arg) |
| Mutation type | NA, inherited from affected mother | | intragenic, de novo | intragenic, de novo | intragenic, unknown | intragenic, de novo |
| Sex | female | female | male | male | male | male |
| Age of examination | 3 years, 8 months | 37 years | 10 years | 3 years | 12 years | 3 years, 9 months |
| Uneventful pregnancy | no (30 WoG) | NA | caesarean (37 WoG) | 33 WoG | NA | yes |
| Birth weight | 2,070 g | NA | normal | normal | NA | normal |
| Birth length | 43 cm | NA | NA | 43.2 cm (normal) | NA | NA |
| Birth OFC | 30 cm | NA | NA | 28cm (<3 rd %) | NA | NA |
| Neonatal hypotonia | yes | NA | yes | no | NA | yes |
| Hypotonia | yes | NA | yes | no | NA | yes |
| Small stature | no | NA | 141.5 cm | mild (91.4 cm; <10 th %) | yes (<3 rd %) | no |
| Low weight | no | NA | no (56.3 kg; >97 th %) | no (17.7 kg; >90 th %) | NA | no |
| ID | yes | mild | moderate | moderate | moderate | mild |
| Microcephaly | mild (<10 th %) | NA | NA | mild (48 cm; <10 th %) | yes (<3 rd %) | mild (<10 th %) |
| Brain anomalies (MRI) | NA | NA | yes ^a | NA | NA | no |
| Seizures | no | NA | yes | no | yes | no |
| Delay in walking | yes | yes | yes | yes | yes (mild) | yes |
| Speech delay | yes | NA | yes | no | yes (no words at 3 years) | yes (only few words) |
| Behavioral anomalies | impaired social interactions | shyness | NA | yes | hyperactivity, autism | very shy |
| Vision or eye problems | strabismus | NA | strabismus, refraction problems | NA | near sighted | strabismus |
| Ptosis and/or blepharophimosis | yes | NA | yes (bilateral) | yes (bilateral) | yes | yes |
| Hand anomalies | no | NA | CD (left second finger) | bilateral CD of fifth finger | bilateral CD of fifth finger | no |
| Feet anomalies | no | NA | long first toe | no | no | CD |

Abbreviations are as follows: %, percentile; CD, camptodactyly; MRI, magnetic resonance imaging; NA, information not available; OFC, occipital frontal circumference; and WoG, weeks of gestation.
^aEnlarged perivascular Virchow-Robin spaces.



Figure 3. Facial Characteristics of the Individuals with *BRPF1* Mutations

Pictures of individuals with *BRPF1* point mutations and deletions. Common features include a roundish face, blepharophimosis and ptosis, downslanted palpebral fissures, temporal narrowing, and a downturned mouth. Ethical approval was obtained from the local ethics committees. For all individuals included in this figure, families also gave consent for publication of the images.

individuals with *BRPF1* disruptions, only one index individual per family was taken into account. Clinical information for individuals with *SETD5* disruptions or 3p25 deletions of both *BRPF1* and *SETD5* was retrieved from the literature.^{4,5,18,19} We observed that disruption of *SETD5* or *BRPF1* tends to lead to mild or moderate ID, whereas all of individuals with severe ID have disruptions of both *SETD5* and *BRPF1*. However, the degree of severity was evaluated by different clinical geneticists and lacked IQ testing for the individuals available, which could be biased. We performed a Fischer's exact test to compare clinical features between these groups. Although the majority of the individuals presented with delay in the acquisition of walking (86%, 83%, and 100% for groups 1, 2, and 3, respectively) and language (86%, 92%, and 100% for groups 1, 2, and 3, respectively), the severity is significantly increased in group 3. All individuals from group 3 acquired walking after 3 years of age (5/5 for group 3 versus 2/19 for groups 1 and 2, p value = 0.0005) and presently have no language (5/5 for group 3 versus 1/19 for groups 1 and 2, p value = 0.0001) (Table 3), suggesting that disruption of both *BRPF1* and *SETD5* contributes to the phenotype of 3p25 deletion syndrome. Interestingly, both genes encode proteins involved in histone modification and gene regulation, and they might have common targets. *SETD5* encodes a methyltransferase involved in the methylation of histones H3 and H4, whereas *BRPF1* binds methylated histone H3 and promotes its acetylation.

To investigate the contribution of *BRPF1* disruption to particular clinical features of the 3p25 microdeletion syndrome, we compared all individuals with disruptions in *BRPF1*, with or without *SETD5* disruptions (group 1 + 3), with those individuals with only *SETD5* disruptions (group 2). A significant difference was observed between

the two groups for the presence of microcephaly or borderline small head size (10/10 in group 1 + 3 versus 1/13 in group 2, p value < 0.0001) and unilateral or bilateral ptosis and/or blepharophimosis (12/12 in group 1 + 3 versus 1/14 in group 2, p value < 0.0001). These eye and/or eyelid anomalies were present in all individuals carrying a disruption of *BRPF1*. Other clinical features (small stature and strabismus) were enriched in individuals with *BRPF1* disruptions; however, these differences were not significant after Bonferroni correction for multiple testing (threshold p value < 0.0017). Better delineating other clinical features driven by *BRPF1* haploinsufficiency will require a larger cohort.

Recently, mutations in *KAT6B* (MIM: 605880) have been associated with syndromic ID, including Ohdo syndrome (MIM: 603736), genitopatellar syndrome (MIM: 606170), blepharophimosis-ptosis-epicanthus inversus syndrome, and even a Noonan-syndrome-like phenotype.^{20–23} Mutations in *KAT6A* (MIM: 601408) are associated with ID with craniofacial dysmorphism, microcephaly or craniosynostosis, feeding difficulties, cardiac defects, and ocular anomalies (MIM: 616268).^{24,25}

Zebrafish and mouse models of *Brpf1* and *BRPF1* disruption, respectively, are reported in the literature.^{13,26} Zebrafish mutants show craniofacial defects, with shifts in segmental identities of craniofacial arches, as a result of a progressive loss of anterior *Hox* gene expression, indicating that *Brpf1* plays a role in patterning the vertebrate head by mediating the expression of *Hox* genes. Mice with homozygous *Brpf1* deletion show embryonic lethality with different embryonic defects, including abnormal neural tube closure.^{16,26} The forebrain-specific deletion of *Brpf1* results in early postnatal lethality and growth retardation. Viable mice show neocortical abnormalities, partial agenesis of the corpus callosum, and

Table 3. Dissection of *SETD5* and *BRPF1* Contributions to Clinical Features of 3p25 Deletion Syndrome

| | Group 1 (<i>BRPF1</i> Only) | | Group 2 (<i>SETD5</i> Only) | | Group 3 (Both <i>SETD5</i> and <i>BRPF1</i>) | |
|--|------------------------------|--------------------|------------------------------|--------|---|--------------------|
| | Percentage | Number | Percentage | Number | Percentage | Number |
| ID | 100% | 7/7 | 100% | 14/14 | 100% | 5/5 |
| Mild or moderate ID | 100% | 6/6 | 100% | 6/6 | 40% | 2/5 |
| Severe ID | 0% | 0/6 | 0% | 0/6 | 60% | 3/5 ^a |
| General Characteristics | | | | | | |
| Uneventful pregnancy (born at term) | 33% | 2/6 | 64% | 9/14 | 40% | 2/5 |
| Low birth parameters | 33% | 2/6 | 8% | 1/13 | 0% | 0/4 |
| Small stature | 43% | 3/7 ^b | 15% | 2/13 | 100% | 4/4 ^a |
| Microcephaly or borderline small head size | 100% | 6/6 ^{b,c} | 8% | 1/13 | 100% | 4/4 |
| Development | | | | | | |
| Walking delay | 86% | 6/7 | 83% | 10/12 | 100% | 5/5 |
| Severe walking delay (>3 years) | 0% | 0/7 | 17% | 2/12 | 100% | 5/5 ^{a,c} |
| Speech delay | 86% | 6/7 | 92% | 12/13 | 100% | 5/5 |
| No speech | 0% | 0/7 | 8% | 1/12 | 100% | 5/5 ^{a,c} |
| Neurological Features | | | | | | |
| Seizures | 29% | 2/7 | 21% | 3/14 | 80% | 4/5 ^a |
| Hypotonia | 67% | 4/6 | 67% | 4/6 | 100% | 4/4 |
| Brain anomalies (MRI) | 67% | 2/3 | 0% | 0/4 | 25% | 1/4 |
| Behavioral anomalies | 71% | 5/7 | 77% | 10/13 | 25% | 1/4 |
| Others Features | | | | | | |
| Strabismus | 80% | 4/5 ^b | 36% | 5/14 | 100% | 4/4 |
| Ptosis and/or blepharophimosis | 100% | 7/7 ^{b,c} | 7% | 1/14 | 100% | 5/5 ^a |
| Hand anomalies | 71% | 5/7 | 50% | 7/14 | 80% | 4/5 |
| Feet anomalies | 57% | 4/7 | 15% | 2/13 | 40% | 2/5 |
| Congenital heart defect | 0% | 0/7 | 15% | 2/13 | 40% | 2/5 |

Clinical information for individuals with *SETD5* point mutations or deletions (group 2) and individuals with large 3p25 deletions encompassing *SETD5* and *BRPF1* was retrieved from the literature.^{4,5,18,19} Clinical information for individuals with *BRPF1* point mutations or small 3p25 deletions reported in this publication (group 1) was retrieved from physicians attending the families. For the sake of avoiding artifacts, one member per family was considered. A 2 × 2 contingency table was made for analyzing the presence of each clinical sign, and because of the small sample size, a two-tailed Fisher's exact test was used to calculate the p value to highlight a statistically significant difference between groups.

^aClinical feature more prevalent when both genes are deleted (group 3) than when only one gene is deleted (groups 1 and 2) (p value < 0.05).

^bClinical feature significantly more associated with *BRPF1* disruption, with or without *SETD5* (group 1 and 3), than with *SETD5* disruption only (group 2) (p value < 0.05).

^cSignificant after Bonferroni correction for multiple testing (p value < 0.0017).

behavioral anomalies.²⁷ Interestingly, the investigators observed an alteration in the expression of several transcription factors involved in developmental processes and upregulation of *Hox* gene expression. These data indicate that *Brpf1* is involved in forebrain development and acts as both an activator and a repressor of gene expression.

Certain chromatin modifiers that are associated with ID when mutated in the germline are also associated with childhood cancer when mutated at the somatic level, for example, *SETBP1* (MIM: 611060) and *KMT2A* (MIM: 159555). Several somatic mutations affecting different re-

gions of *BRPF1* have been reported in childhood leukemia²⁸ and adult medulloblastoma.²⁹

In conclusion, we report here that LoF point mutations and small deletions affecting *BRPF1* are responsible for a syndromic form of ID associated with eye and/or eyelid phenotype, i.e., ptosis and/or blepharophimosis. *BRPF1* encodes the third member of the HAT KAT6A-KAT6B complex, which is involved in ID when functionally impaired.

We have therefore shown that *BRPF1*, together with *SETD5*, contributes to the severity of the 3p25 deletion syndrome phenotype and is responsible for some specific clinical features, such as ptosis and blepharophimosis.

Accession Numbers

The accession number for the data reported in this paper is ClinVar: SCV000328673.1.

Supplemental Data

Supplemental Data include two figures and three tables and can be found with this article online at <http://dx.doi.org/10.1016/j.ajhg.2016.11.010>.

Acknowledgments

The authors thank the families for their participation in this study. The authors also thank Fondation Jerome Lejeune, Fondation Maladies Rares, and Association APLM for financial support. This study was also supported by grant ANR-10-LABX-0030-INRT, a French state fund managed by the Agence Nationale de la Recherche under the frame program Investissements d'Avenir ANR-10-IDEX-0002-02. The authors also thank all members of the Strasbourg Hospital molecular diagnostic lab, the Clinical Genetics Service of Prof. Hélène Dollfus, the Institut Génétique Biologie Moléculaire Cellulaire sequencing platform, and UMR_S 1112 (Bernard Jost, Stéphanie Le Gras, Mathieu Jung, Jean Muller, and Véronique Geoffroy) for their technical and bioinformatics support. We also thank Sylvain Daujat, Robert Schneider, Federica Evangelista, Tiago Baptista, and Lazlo Tora for histone H3 antibodies and technical advice; and Xiang-Jiao Yang for the cDNA of *BRPF1*, *KAT6A*, *ING5*, and *MEAF6* expression plasmids and technical help. J.J. is an employee of GeneDx, and A. Pujol is a consultant for GeneDx.

Received: August 16, 2016

Accepted: November 11, 2016

Published: December 8, 2016

Web Resources

ClinVar, <http://www.ncbi.nlm.nih.gov/clinvar/>
dbSNP, <http://www.ncbi.nlm.nih.gov/projects/SNP/>
Decipher, <https://decipher.sanger.ac.uk/>
ExAC Browser, <http://exac.broadinstitute.org/>
GeneMatcher, <https://genematcher.org/>
Integrative Genomics Viewer (IGV), <http://www.broadinstitute.org/igv/>
Mutation Nomenclature, <http://www.hgvs.org/mutnomen/recs.html>
NHLBI Exome Sequencing Project (ESP) Exome Variant Server, <http://evs.gs.washington.edu/EVS/>
OMIM, <http://www.omim.org/>
RefSeq, <http://www.ncbi.nlm.nih.gov/RefSeq>
UCSC Genome Browser, <http://genome.ucsc.edu/>

References

1. Narahara, K., Kikkawa, K., Murakami, M., Hiramoto, K., Namba, H., Tsuji, K., Yokoyama, Y., and Kimoto, H. (1990). Loss of the 3p25.3 band is critical in the manifestation of del(3p) syndrome: karyotype-phenotype correlation in cases with deficiency of the distal portion of the short arm of chromosome 3. *Am. J. Med. Genet.* 35, 269–273.
2. Dikow, N., Maas, B., Karch, S., Granzow, M., Janssen, J.W., Jauch, A., Hinderhofer, K., Sutter, C., Schubert-Bast, S., Anderlid, B.M., et al. (2014). 3p25.3 microdeletion of GABA transporters *SLC6A1* and *SLC6A11* results in intellectual disability, epilepsy and stereotypic behavior. *Am. J. Med. Genet. A.* 164A, 3061–3068.
3. Rauch, A., Wieczorek, D., Graf, E., Wieland, T., Endeke, S., Schwarzmayr, T., Albrecht, B., Bartholdi, D., Beygo, J., Di Donato, N., et al. (2012). Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. *Lancet* 380, 1674–1682.
4. Grozeva, D., Carss, K., Spasic-Boskovic, O., Parker, M.J., Archer, H., Firth, H.V., Park, S.M., Canham, N., Holder, S.E., Wilson, M., et al.; UK10K Consortium (2014). De novo loss-of-function mutations in *SETD5*, encoding a methyltransferase in a 3p25 microdeletion syndrome critical region, cause intellectual disability. *Am. J. Hum. Genet.* 94, 618–624.
5. Kuechler, A., Zink, A.M., Wieland, T., Lüdecke, H.J., Cremer, K., Salviati, L., Magini, P., Najafi, K., Zweier, C., Czeschik, J.C., et al. (2015). Loss-of-function variants of *SETD5* cause intellectual disability and the core phenotype of microdeletion 3p25.3 syndrome. *Eur. J. Hum. Genet.* 23, 753–760.
6. Geoffroy, V., Pizot, C., Redin, C., Piton, A., Vasli, N., Stoetzel, C., Blavier, A., Laporte, J., and Muller, J. (2015). VaRank: a simple and powerful tool for ranking genetic variants. *PeerJ* 3, e796.
7. Redin, C., Gérard, B., Lauer, J., Herenger, Y., Muller, J., Quartier, A., Masurel-Paulet, A., Willems, M., Lesca, G., El-Chehadeh, S., et al. (2014). Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing. *J. Med. Genet.* 51, 724–736.
8. Lek, M., Karczewski, K.J., Minikel, E.V., Samocha, K.E., Banks, E., Fennell, T., O'Donnell-Luria, A.H., Ware, J.S., Hill, A.J., Cummings, B.B., et al.; Exome Aggregation Consortium (2016). Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 536, 285–291.
9. Lowry, W.E., Richter, L., Yachechko, R., Pyle, A.D., Tchiew, J., Sridharan, R., Clark, A.T., and Plath, K. (2008). Generation of human induced pluripotent stem cells from dermal fibroblasts. *Proc. Natl. Acad. Sci. USA* 105, 2883–2888.
10. McRae, J.F., Clayton, S., Fitzgerald, T.W., Kaplanis, J., Prigmore, E., Rajan, D., Sifrim, A., Aitken, S., Akawi, N., Alvi, M., et al. (2016). Prevalence, phenotype and architecture of developmental disorders caused by de novo mutation. *bioRxiv*. <http://dx.doi.org/10.1101/049056>.
11. Xu, B., Roos, J.L., Dexheimer, P., Boone, B., Plummer, B., Levy, S., Gogos, J.A., and Karayiorgou, M. (2011). Exome sequencing supports a de novo mutational paradigm for schizophrenia. *Nat. Genet.* 43, 864–868.
12. Ullah, M., Pelletier, N., Xiao, L., Zhao, S.P., Wang, K., Degerny, C., Tahmasebi, S., Cayrou, C., Doyon, Y., Goh, S.L., et al. (2008). Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes. *Mol. Cell. Biol.* 28, 6828–6843.
13. Laue, K., Daujat, S., Crump, J.G., Plaster, N., Roehl, H.H., Kimmel, C.B., Schneider, R., Hammerschmidt, M.; and Tübingen 2000 Screen Consortium (2008). The multidomain protein Brpf1 binds histones and is required for Hox gene expression and segmental identity. *Development* 135, 1935–1946.
14. Doyon, Y., Cayrou, C., Ullah, M., Landry, A.J., Côté, V., Sellack, W., Lane, W.S., Tan, S., Yang, X.J., and Côté, J. (2006). ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. *Mol. Cell* 21, 51–64.

15. Voss, A.K., Collin, C., Dixon, M.P., and Thomas, T. (2009). Moz and retinoic acid coordinately regulate H3K9 acetylation, Hox gene expression, and segment identity. *Dev. Cell* *17*, 674–686.
16. You, L., Yan, K., Zou, J., Zhao, H., Bertos, N.R., Park, M., Wang, E., and Yang, X.J. (2015). The chromatin regulator Brpf1 regulates embryo development and cell proliferation. *J. Biol. Chem.* *290*, 11349–11364.
17. Hibiya, K., Katsumoto, T., Kondo, T., Kitabayashi, I., and Kudo, A. (2009). Brpf1, a subunit of the MOZ histone acetyltransferase complex, maintains expression of anterior and posterior Hox genes for proper patterning of craniofacial and caudal skeletons. *Dev. Biol.* *329*, 176–190.
18. Ellery, P.M., Ellis, R.J., and Holder, S.E. (2014). Interstitial 3p25 deletion in a patient with features of 3p deletion syndrome: further evidence for the role of SRGAP3 in mental retardation. *Clin. Dysmorphol.* *23*, 29–31.
19. Pinto, D., Delaby, E., Merico, D., Barbosa, M., Merikangas, A., Klei, L., Thiruvahindrapuram, B., Xu, X., Ziman, R., Wang, Z., et al. (2014). Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. *Am. J. Hum. Genet.* *94*, 677–694.
20. Campeau, P.M., Lu, J.T., Dawson, B.C., Fokkema, I.F., Robertson, S.P., Gibbs, R.A., and Lee, B.H. (2012). The KAT6B-related disorders genitopatellar syndrome and Ohdo/SBBYS syndrome have distinct clinical features reflecting distinct molecular mechanisms. *Hum. Mutat.* *33*, 1520–1525.
21. Clayton-Smith, J., O'Sullivan, J., Daly, S., Bhaskar, S., Day, R., Anderson, B., Voss, A.K., Thomas, T., Biesecker, L.G., Smith, P., et al. (2011). Whole-exome-sequencing identifies mutations in histone acetyltransferase gene KAT6B in individuals with the Say-Barber-Biesecker variant of Ohdo syndrome. *Am. J. Hum. Genet.* *89*, 675–681.
22. Kraft, M., Cirstea, I.C., Voss, A.K., Thomas, T., Goehring, I., Sheikh, B.N., Gordon, L., Scott, H., Smyth, G.K., Ahmadian, M.R., et al. (2011). Disruption of the histone acetyltransferase MYST4 leads to a Noonan syndrome-like phenotype and hyperactivated MAPK signaling in humans and mice. *J. Clin. Invest.* *121*, 3479–3491.
23. Yu, H.C., Geiger, E.A., Medne, L., Zackai, E.H., and Shaikh, T.H. (2014). An individual with blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) and additional features expands the phenotype associated with mutations in KAT6B. *Am. J. Med. Genet. A.* *164A*, 950–957.
24. Arboleda, V.A., Lee, H., Dorrani, N., Zadeh, N., Willis, M., Macmurdo, C.F., Manning, M.A., Kwan, A., Hudgins, L., Barthelmy, E., et al.; UCLA Clinical Genomics Center (2015). De novo nonsense mutations in KAT6A, a lysine acetyltransferase gene, cause a syndrome including microcephaly and global developmental delay. *Am. J. Hum. Genet.* *96*, 498–506.
25. Tham, E., Lindstrand, A., Santani, A., Malmgren, H., Nesbitt, A., Dubbs, H.A., Zackai, E.H., Parker, M.J., Millan, F., Rosenbaum, K., et al. (2015). Dominant mutations in KAT6A cause intellectual disability with recognizable syndromic features. *Am. J. Hum. Genet.* *96*, 507–513.
26. You, L., Zou, J., Zhao, H., Bertos, N.R., Park, M., Wang, E., and Yang, X.J. (2015). Deficiency of the chromatin regulator BRPF1 causes abnormal brain development. *J. Biol. Chem.* *290*, 7114–7129.
27. You, L., Yan, K., Zou, J., Zhao, H., Bertos, N.R., Park, M., Wang, E., and Yang, X.J. (2015). The lysine acetyltransferase activator Brpf1 governs dentate gyrus development through neural stem cells and progenitors. *PLoS Genet.* *11*, e1005034.
28. Huether, R., Dong, L., Chen, X., Wu, G., Parker, M., Wei, L., Ma, J., Edmonson, M.N., Hedlund, E.K., Rusch, M.C., et al. (2014). The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. *Nat. Commun.* *5*, 3630.
29. Kool, M., Jones, D.T., Jäger, N., Northcott, P.A., Pugh, T.J., Hovestadt, V., Piro, R.M., Esparza, L.A., Markant, S.L., Remke, M., et al.; ICGC PedBrain Tumor Project (2014). Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothed inhibition. *Cancer Cell* *25*, 393–405.

The American Journal of Human Genetics, Volume 100

Supplemental Data

Mutations in Histone Acetylase Modifier

BRPF1 Cause an Autosomal-Dominant Form

of Intellectual Disability with Associated Ptosis

Francesca Mattioli, Elise Schaefer, Alex Magee, Paul Mark, Grazia M. Mancini, Klaus Dieterich, Gretchen Von Allmen, Marielle Alders, Charles Coutton, Marjon van Slegtenhorst, Gaëlle Vieville, Mark Engelen, Jan Maarten Cobben, Jane Juusola, Aurora Pujol, Jean-Louis Mandel, and Amélie Piton

Supplemental Figures

Figure S1.




Figure S1. Effect of the c.1052_1053del variant on histone H3 acetylation level. (A) Global histone H3 acetylation level was compared between individual II-5 and three unrelated control individuals. Histone were extracted from fibroblasts and H3 acetylation level was measured (experiments performed in triplicate, error bars indicate the SD) using the EpiQuik Global Histone H3 kit. (B) Immunoblot performed on histone extracts from fibroblasts of individual II-5 and three unrelated control individuals (four extractions per individual) with specific anti-H3K9ac (Abcam, ab4441), anti-H3K14ac and anti-H3K23ac (cell signaling, #9674) antibodies and global H3 antibody (upstate, cat 06755, lot 31949). No difference was observed in H3K9 or H3K14 acetylation intensity between patient II-5 and controls when normalized by the intensities obtained for global H3. A non-significant decrease of H3K23 acetylation level was however observed for the patient II-5 compared to the three unrelated controls (experiments performed on four histone extractions per individuals) (C) HeLa cells were cotransfected with MOZ/KAT6A, ING5 and MEAF6 cDNAs with or without wild-type or mutant BRPF1 cDNA. Oligonucleosomes were extracted and *in vitro* histone acetylation assays were performed as previously described⁷. Acetylation levels were analyzed by immunoblotting using antibodies against histone H3 and its acetylated forms.

Figure S2.




Figure S2. Significant increase in HOXD8 expression level was observed in individual II-5 cells. Quantitative real-time PCR was performed on reverse-transcribed mRNA extracted from fibroblasts of patient II-5 and of four unrelated controls (experiments performed on four different extractions per individual). The relative expression of HOXD8 *v.s.* GAPDH was calculated using the $2^{-(\Delta\Delta C_t)}$ method. Error bars indicate the SD of four independent experiments. A t-test was performed and showed a significant increase of *HOXD8* mRNA level in patient's fibroblasts.

Supplemental Tables

Table S1.

| Gene | Variation | Status | Type of variation | Consequensis | At the protein level | dbSNP | ExAC | SIFT | Polyphen2 |
|-------------|------------------------------|---------------|--------------------------|---------------------|-----------------------------|--------------|-----------------|--------------------|---------------------------|
| CDCA5 | NM_080668.3:c.650G>A | heterozygous | substitution | missense | p.Arg217His | rs771200184 | 1 heterozygous | Deleterious (0) | POSSIBLY DAMAGING (0.828) |
| CHRNA5 | NM_005199: c.143C>T | heterozygous | substitution | missense | p.Ser48Leu | rs370022034 | - | Deleterious (0.04) | BENIGN (0.108) |
| TBC1D10C | NM_198517: c.1279C>T | heterozygous | substitution | missense | p.Pro427Ser | rs756681324 | 15 heterozygous | Tolerated (0.12) | BENIGN (0.005) |
| BRPF1 | NM_001003694: c.1052_1053del | heterozygous | deletion | frameshift | p.Val351Glyfs*8 | - | - | NA | NA |

Table S1. Rare non-synonymous variants identified by WES and common to the three affected family members sequenced.

Table S2.

| Chrom | Position | Reference | Alternate | Protein Consequence | Transcript Consequence | Annotation | Allele Count | Allele Number | Number of homozygous | Population | Comments |
|-------|----------|-----------|-----------|------------------------|--------------------------------|-----------------|-----------------|------------------|-------------------------|---------------------------|--|
| 3 | 9783787 | C | T | p.Gln645Ter | ENST00000383829.2:c.1933C>T | stop gained | 1 | 121 384 | 0 | African | The variation is present in 14/65 reads. It could be a mosaic variant |
| 3 | 9785260 | A | C | p.? | ENST00000383829.2:c.2312-2A>C | splice acceptor | 1 | 112 398 | 0 | European (Non-Finnish) | It affects the acceptor splice site of exon 8 (324 nts length), might create an in frame deletion of 108 a.a (Ala771 to Lys878) |
| 3 | 9785263 | A | G | p.? | ENST00000469066.1:n.217-2A>G | splice acceptor | 6 | 113 094 | 0 | LATINO | It affects a known processed transcript, not coding for a protein |
| 3 | 9786193 | G | A | p.? | ENST00000383829.2:c.2920+1G>A | splice donor | 1 | 105 458 | 0 | LATINO | It affects the donor splice site of exon 9 (285 nts length), might create an in frame deletion of 95 a.a (Gly879 to Met973). Rs191236303 |
| 3 | 9787255 | AG | A | p.? | ENST00000383829.2:c.3069-1delG | splice acceptor | 1 | 121 324 | 0 | European (Non-Finnish) | It affects 137 nts, might create a frameshift the acceptor splice site of exon 11 (137 nts length), might cause a frameshift |

Table S2. Splice and nonsense variants identified in *BRPF1* in the ExAC general population

Table S3.

| | Group1 | Group 2 | | | | Group 3 |
|--|--|----------------------------|--------------------------|--|---------------------------|--|
| <i>Reference</i> | <i>this report</i> | <i>Grozeva et al. 2014</i> | <i>Pinto et al. 2014</i> | <i>Kuechler et al. 2015</i> (Patient 1, 2, 3, Riess et al. 201, Kellogg et al. 2013) | <i>Ellery et al. 2014</i> | <i>Kuechler et al. 2015</i> (Patient 4, 5, 6, Gunnarsson et al., Peltekova et al.) |
| Type of mutation | <i>BRPF1</i> LoF or deletions w/o <i>SETD5</i> | <i>SETD5</i> LoF | <i>SETD5</i> deletion | <i>SETD5</i> LoF and deletions w/ot <i>BRPF1</i> | <i>SETD5</i> deletion | 3p25 deletions encompassing both <i>SETD5</i> and <i>BRPF1</i> |
| Sex | 6M, 1F | 7M | M | 4F, 1M | M | 4F, 1M |
| ID severity: | 7/7 | 7/7 | 1 | 5/5 | 1 | 5/5 |
| severity: | | | | | | |
| mild | 3/6 | | 1 | 4/5 | | 1/5 |
| moderate | 3/6 | | | 1/5 | | 1/5 |
| severe | 0/6 | | | 0/5 | | 3/5 |
| General characteristics: | | | | | | |
| Uneventful pregnancy (born at term) | 2/6 | 4/7 | 1 | 4/5 | 0 | 2/5 |
| low birth weight-height/growth retardation | 2/6 | 0/7 | 0 | 1/5 | n.a. | 0/4 |
| Small stature | 3/7 | 1/7 | 0 | 1/5 | | 4/4 |
| Microcephaly/smaller head size | 6/6 | 1/7 | 0 | 0/5 | n.a. | 4/4 |
| Development | | | | | | |
| Mild walking delay (>18mo <3y) | 6/7 | 6/7 | 0 | 4/4 | | 0/5 |
| Severe delay at walk (>3y) | 0/7 | 2/7 | 0 | 0/4 | | 5/5 |
| speech delay | 6/7 | 7/7 | 1 | 3/4 | 1 | 5/5 |

| | | | | | | |
|--------------------------------|-----|-----------|------|-----|------|-----|
| no speech | 0/7 | 1/7 | 0 | 0/3 | 0 | 5/5 |
| Neurological features | | | | | | |
| Behavioral anomalies | 5/7 | 5/7 | 1 | 4/5 | n.a. | 1/5 |
| Brain anomalies (MRI) | 2/3 | 0 (6n.a.) | n.a. | 0/3 | n.a. | 1/4 |
| Hypotonia | 4/6 | n.a. | n.a. | 3/5 | 1 | 4/4 |
| Seizures | 2/7 | 0/7 | 0 | 2/5 | 1 | 4/5 |
| Facial dysmorphisms | | | | | | |
| Strabismus | 4/5 | 1/7 | | 4/5 | | 3/5 |
| Ptosis and/or blepharophimosis | 7/7 | 1/7 | 0 | 0/5 | | 5/5 |
| Limbs | | | | | | |
| Hand anomalies | 5/7 | 2/7 | 0 | 4/5 | 1 | 4/5 |
| Feet anomalies | 4/7 | 1/7 | 0 | 1/4 | | 2/5 |
| Others features: | | | | | | |
| Congenital heart defects | 0/7 | 2/7 | 0 | 0/5 | | 2/5 |

Table S3. Clinical features of patients reported in literature with mutations/deletions of *SETD5* (Group 2) or deletions encompassing both *SETD5* and *BRPF1* (Group 3)

Supplemental References

1. Geoffroy, V., Pizot, C., Redin, C., Piton, A., Vasli, N., Stoetzel, C., Blavier, A., Laporte, J., and Muller, J. (2015). VaRank: a simple and powerful tool for ranking genetic variants. *PeerJ* 3, e796.
2. Redin, C., Gerard, B., Lauer, J., Herenger, Y., Muller, J., Quartier, A., Masurel-Paulet, A., Willems, M., Lesca, G., El-Chehadeh, S., et al. (2014). Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing. *J Med Genet* 51, 724-736.
3. Ellery, P.M., Ellis, R.J., and Holder, S.E. (2014). Interstitial 3p25 deletion in a patient with features of 3p deletion syndrome: further evidence for the role of SRGAP3 in mental retardation. *Clin Dysmorphol* 23, 29-31.
4. Grozeva, D., Carss, K., Spasic-Boskovic, O., Parker, M.J., Archer, H., Firth, H.V., Park, S.M., Canham, N., Holder, S.E., Wilson, M., et al. (2014). De novo loss-of-function mutations in SETD5, encoding a methyltransferase in a 3p25 microdeletion syndrome critical region, cause intellectual disability. *Am J Hum Genet* 94, 618-624.
5. Kuechler, A., Zink, A.M., Wieland, T., Ludecke, H.J., Cremer, K., Salviati, L., Magini, P., Najafi, K., Zweier, C., Czeschik, J.C., et al. (2015). Loss-of-function variants of SETD5 cause intellectual disability and the core phenotype of microdeletion 3p25.3 syndrome. *Eur J Hum Genet* 23, 753-760.
6. Pinto, D., Delaby, E., Merico, D., Barbosa, M., Merikangas, A., Klei, L., Thiruvahindrapuram, B., Xu, X., Ziman, R., Wang, Z., et al. (2014). Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. *Am J Hum Genet* 94, 677-694.
7. Ullah, M., Pelletier, N., Xiao, L., Zhao, S.P., Wang, K., Degerny, C., Tahmasebi, S., Cayrou, C., Doyon, Y., Goh, S.L., et al. (2008). Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes. *Mol Cell Biol* 28, 6828-6843.